Building Health Check LLC, a distributor and marketer of the Halo Disinfection System, which eliminates 99.9999 percent of Clostridium difficile (C. diff) spores in entire rooms announced the registration with the U.S. Environmental Protection Agency (EPA Registration No. 84526-6). It is the first disinfectant fogging system validated by the EPA to kill Clostridium difficile (C. diff) spores.
The Halo Disinfection System also kills many other pathogens typically found in hospitals and health care environments using a patented solution of hydrogen peroxide and ionic silver applied in a dry mist by a cost-effective portable fogger.
The Halo Disinfection System incorporates the HaloFogger using the health-care-grade HaloMist solution. The system is an easy-to-use, economic and highly effective alternative to “spray & wipe”, UV light and other disinfecting strategies. During hands-free use, the HaloFogger converts the HaloMist into a clear, odorless dry mist that reaches in and around every surface in an enclosed area. There is no need to mix the solution, nor is there any need for rinsing or wiping.
After application, HaloMist decomposes into water and oxygen molecules, dries on contact and does not harm sensitive medical equipment. The system does not contain or produce chlorine, hypochlorite (bleach), alcohol, aldehydes, phenols, ammonium compounds or sodium hydroxide. These toxins and harsh chemicals can be found in many other disinfecting solutions.
During a recent study of the HDS system at Pennsylvania Hospital, a 496-bed urban teaching hospital in Philadelphia, infection control experts cut the rate of C. diff infections by 66 percent after deploying the HDS system in patient rooms, operating rooms and treatment areas. In a similar study, Southwestern Vermont Medical Center experienced a period of more than six months without a single hospital-acquired C. diff case. These results suggest that the system offers a comparatively simple, inexpensive way to comply with a federal mandate to reduce C. diff HAI infections 30 percent.